Eren Arslan Davulcu, Zühal Demirci, Umut Yılmaz, Muhlis Cem Ar, Hava Üsküdar Teke, Volkan Karakuş, Rafiye Çiftçiler, Cem Selim, İrfan Yavaşoğlu, Salih Sertaç Durusoy, Vahap Okan, Aydan Akdeniz, Alkım Yolcu, İsmet Aydoğdu, Tekin Güney, Asu Fergün Yılmaz, Fahri Şahin
Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed...
January 2023: Indian Journal of Hematology & Blood Transfusion